Navigation Links
Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase III clinical trial data presented today at the XXI International Society on Thrombosis and Haemostasis (ISTH) Congress demonstrate that once-daily rivaroxaban achieved superior efficacy in the prevention of venous thromboembolism (VTE) in patients undergoing knee replacement surgery in a head-to-head comparison with enoxaparin, the current standard of care. Patients in the RECORD3 (REgulation of Coagulation in major Orthopaedic surgery reducing the Risk of DVT and PE) study who were treated with rivaroxaban demonstrated a 49% relative risk reduction (RRR) (p less than 0.001) in the composite primary endpoint of deep vein thrombosis (DVT), non-fatal pulmonary embolism (PE) and all-cause mortality compared to those treated with enoxaparin. A 62% reduction of risk (p=0.01) for developing major VTE (the composite of proximal DVT, non-fatal PE and VTE-related death) - the secondary endpoint of the trial - was observed in the patients treated with rivaroxaban. Rivaroxaban also demonstrated a similarly low rate of major bleeding compared to enoxaparin (0.6% and 0.5%, respectively).

Rivaroxaban is an investigational, oral, once-daily direct Factor Xa inhibitor. It is an anticoagulant - a drug designed to prevent and treat blood clots - in advanced clinical development for the prevention and treatment of thrombosis in acute and chronic settings, enabling convenient administration in both the hospital and at home.

Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development L.L.C. (J&JPRD), and Bayer HealthCare AG.

Lead RECORD3 investigator, Michael R. Lassen, MD, of Hoersholm Hospital, University of Copenhagen, Denmark, commented: "The RECORD3 results are exciting, as they indicate that rivaroxaban may better meet the needs of many patients undergoing orthopaedic surgery. It's an important step for t
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:10/22/2014)... HAMILTON, N.J. , Oct. 22, 2014 ... CLIA-certified, CAP-accredited laboratory which specializes in high ... that it is now offering new Cystic ... including next- generation DNA sequencing platforms. ... a genetically inherited multisystem disorder that affects ...
(Date:10/22/2014)... , Oct 22, 2014 Antigen Discovery ... Irvine, California , announced the receipt of a ... Innovation Research award (SBIR) from the National Institute of Dental and ... the development of a Pan-HIV Protein Microarray Chip, which ... and HIV-2 subtypes and aid in the development of ...
(Date:10/22/2014)... AVACEN Medical announced today that its AVACEN ... clearance by the U.S. Food and Drug Administration. This ... the Internet for: the temporary relief of joint ... and sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... is a sophisticated medical device incorporating over 3,000 firmware ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... International,Inc. (NYSE: BAX ) announced today that ... IX proteins to treat hemophilia B.,Baxter will develop ... of acute bleeding episodes and a chemically modified, ... of bleeding in,hemophilia B patients. Hemophilia B is ...
... Nanoparticles May Deliver Treatments to Human,Organs -, PHILADELPHIA, ... iron-bearing particles to drive healthy cells to,targeted sites in ... to,a new method of delivering cells and genes to ... http://www.newscom.com/cgi-bin/prnh/20080107/DC10966 ), The study team, led by ...
Cached Medicine Technology:Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 3Researchers Use Magnetism to Target Cells to Animal Arteries 2Researchers Use Magnetism to Target Cells to Animal Arteries 3Researchers Use Magnetism to Target Cells to Animal Arteries 4
(Date:10/25/2014)... October,s shorter, darker days can trigger a type of ... expert. People affected by seasonal affective disorder, ... and even have trouble getting out of bed. In ... Angelos Halaris, a professor in the department of psychiatry ... of Medicine. "Seasonal affective disorder should not be ...
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
(Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
(Date:10/22/2014)... Lexington, Kentucky (PRWEB) October 22, 2014 ... an agreement that will change the current location of ... Road to South Limestone across from the University of ... be a state-of-the-art ambulatory care center, owned and operated ... meet the orthopaedic needs of children and their families ...
(Date:10/22/2014)... D.C. (PRWEB) October 22, 2014 With the ... a national survey by the American Institutes for Research (AIR) ... know how to use health insurance, but 42 percent say ... a plan’s details before signing up for coverage. , The ... with only 20 percent able to calculate correctly how much ...
Breaking Medicine News(10 mins):Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4
... told yesterday about a surgeon Dr Jerome Blanchard who had ... only a diseased one. , ,The disciplinary hearing ... the wrong kidney from a patient and left her dependent ... medical notes. Dr Jerome Blanchard took out his patient’s transplant ...
... conclusion drawn by the doctors after treating 65 million ... therapy// to bring the blood pressure to normal range ... ,A number of clinical studies since long has shown ... Professor of Medicine; Brigham and Women’s Hospital and Harward ...
... Dutch study contradicts the popular belief that the effect ... impact on the soldier’s partner and children//. It highlights ... any significant way. ,Psychiatrist Arend Veeninga, in ... no scientific basis to the theory that ‘war trauma ...
... has been found to suppress bladder pain associated with ... is a analog of a metabolite of THC, the ... study presented at the annual meeting of the American ... in the treatment of hypersensitive bladder disorders and similar ...
... its presence in the Indian market and gain wider acceptability, ... punch of health// to its India portfolio, possibly by early ... beverage solutions in the non-alcohol segment. This would include not ... Cola India chief Atul Singh told PTI here. ...
... Manchester feel that Statins, A cholesterol-lowering drug should be prescribed ... reduce the heart diseases. ,The researchers looked at ... the mid-1990s, and recorded how many of them had a ... calculate as to how many people would need to have ...
Cached Medicine News:Health News:Consultant Bungles A Kidney Surgery 2Health News:Combination Drug Therapy For Hypertension 2Health News:Bladder Pain Suppressed By Marijuana-Derived Drug 2Health News:A New Study Feels That The UK heart drug Guidelines Not Enough 2
... sunwear, inspired by modern American ... with long lasting wearability. The ... include sophistication, elegance and enduring ... modern shapes, classic styling and ...
... mounting technology has redefined rimless collections forever.,The ... at the end of each frame mounting. ... the bushing that mounts within the lens. ... secure fit is created that far exceeds ...
... collection celebrates the 85th anniversary of the ... feel, the unmistakable icons that made GUCCI ... and sunglass collection, dedicated to a multifaceted ... design that is the hallmark of the ...
... Whisper NG Erbium YAG Extended Ablation laser ... true laser peel with outstanding results and no ... a proprietary fluence level with an extra long ... skin. Peeling is spread over 3-5 days, ...
Medicine Products: